Good Life Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.1M | Sell |
54,302
-114
| -0.2% | -$21.2K | 0.63% | 33 |
|
|
2025
Q1 | $11.4M | Buy |
54,416
+2,319
| +4% | +$451K | 0.8% | 26 |
|
|
2024
Q4 | $9.26M | Buy |
52,097
+1,360
| +3% | +$250K | 0.67% | 26 |
|
|
2024
Q3 | $10M | Buy |
50,737
+2,790
| +6% | +$521K | 0.62% | 32 |
|
|
2024
Q2 | $8.22M | Buy |
47,947
+2,201
| +5% | +$365K | 0.68% | 27 |
|
|
2024
Q1 | $8.33M | Buy |
45,746
+495
| +1% | +$85.3K | 0.74% | 28 |
|
|
2023
Q4 | $7.01M | Buy |
45,251
+2,228
| +5% | +$325K | 0.69% | 30 |
|
|
2023
Q3 | $6.41M | Buy |
43,023
+20,186
| +88% | +$2.96M | 0.73% | 31 |
|
|
2023
Q2 | $3.08M | Buy |
22,837
+2,721
| +14% | +$399K | 0.35% | 58 |
|
|
2023
Q1 | $3.21M | Buy |
20,116
+1,583
| +9% | +$242K | 0.41% | 57 |
|
|
2022
Q4 | $3M | Buy |
18,533
+7,322
| +65% | +$1.12M | 0.41% | 56 |
|
|
2022
Q3 | $1.5M | Buy |
11,211
+190
| +2% | +$27.3K | 0.22% | 91 |
|
|
2022
Q2 | $1.69M | Sell |
11,021
-381
| -3% | -$58.2K | 0.24% | 87 |
|
|
2022
Q1 | $1.85M | Sell |
11,402
-850
| -7% | -$123K | 0.23% | 85 |
|
|
2021
Q4 | $1.66M | Buy |
12,252
+289
| +2% | +$34.1K | 0.2% | 91 |
|
|
2021
Q3 | $1.29M | Buy |
11,963
+783
| +7% | +$89.5K | 0.18% | 104 |
|
|
2021
Q2 | $1.26M | Sell |
11,180
-963
| -8% | -$108K | 0.24% | 76 |
|
|
2021
Q1 | $1.31M | Buy |
12,143
+789
| +7% | +$84.4K | 0.26% | 73 |
|
|
2020
Q4 | $1.21M | Sell |
11,354
-159
| -1% | -$15.3K | 0.28% | 66 |
|
|
2020
Q3 | $1.01M | Sell |
11,513
-387
| -3% | -$36.4K | 0.27% | 71 |
|
|
2020
Q2 | $1.17M | Buy |
11,900
+436
| +4% | +$38.4K | 0.35% | 64 |
|
|
2020
Q1 | $878K | Sell |
11,464
-116
| -1% | -$9.88K | 0.32% | 73 |
|
|
2019
Q4 | $1.02M | Buy |
11,580
+339
| +3% | +$28.1K | 0.29% | 66 |
|
|
2019
Q3 | $859K | Buy |
11,241
+414
| +4% | +$28.4K | 0.27% | 72 |
|
|
2019
Q2 | $792K | Buy |
10,827
+1,499
| +16% | +$118K | 0.23% | 78 |
|
|
2019
Q1 | $752K | Sell |
9,328
-16
| -0.2% | -$1.31K | 0.22% | 80 |
|
|
2018
Q4 | $861K | Sell |
9,344
-1,309
| -12% | -$115K | 0.28% | 68 |
|
|
2018
Q3 | $1.01M | Buy |
10,653
+593
| +6% | +$56.2K | 0.29% | 63 |
|
|
2018
Q2 | $933K | Buy |
10,060
+537
| +6% | +$52.4K | 0.3% | 62 |
|
|
2018
Q1 | $871K | Buy |
9,523
+6,250
| +191% | +$687K | 0.3% | 62 |
|
|
2017
Q4 | $328K | Sell |
3,273
-201
| -6% | -$18.9K | 0.1% | 151 |
|
|
2017
Q3 | $320K | Buy |
3,474
+72
| +2% | +$5.48K | 0.12% | 138 |
|
|
2017
Q2 | $247K | Buy |
+3,402
| New | +$229K | 0.11% | 163 |
|
Other funds holding ABBV
Good Life Advisors's ABBV Position: Q2 2025 in Review
Good Life Advisors reduced its AbbVie (ABBV) stake by 0.21% in Q2 2025, selling an estimated $21.2K and leaving 54,302 shares worth $10.1M. The position accounts for 0.63% of the portfolio, ranked #33.
Good Life Advisors first reported a position in ABBV in Q2 2017 and has held it in 33 quarters since. The position peaked at $11.4M in Q1 2025. 3,781 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.
- Good Life Advisors held 54,302 shares of AbbVie worth $10.1M as of Q2 2025.
- Good Life Advisors sold 114 AbbVie shares in Q2 2025, an estimated $21.2K.
- AbbVie made up 0.63% of Good Life Advisors's portfolio in Q2 2025, its #33 holding.
- Good Life Advisors first reported a position in AbbVie in Q2 2017 and has held it in 33 quarters since.
- Good Life Advisors's AbbVie position peaked at $11.4M in Q1 2025.
- 3,781 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.
Based on Good Life Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.